Three CDMOs have separately announced expansions in their antibody-drug conjugate (ADC) manufacturing capabilities and capacity on opposite sides of the Atlantic. This has come on the back of growing interest in this modality in the treatment of cancer, which has been forecast to grow at 15%/year to 2028.
ICL has held the groundbreaking ceremony for a $400 million, 13,000 m2, 30,000 tones/year battery materials manufacturing facility at its Carondolet site at St Louis, Missouri. Present at the event on 8 August were Secretary of Energy Jennifer M. Granholm, whose department granted $197 million towards building the facility under the Investing in America agenda, and Missouri governor Mike Parson.
Merck KGaA’s Life Science business sector has launched ChetoSensar, a technology that improves the solubility of antibody-drug conjugates (ADCs). Over 20% of ADC candidates are terminated in clinical trials because of poor solubility. The company said that this supports it efforts to double its ADC and HPAPI capacity in the near future.
